ANXA10

Across TCGA pan-cancer cohorts, ANXA10 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated ANXA10 data layer compared with 1 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANXA10 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANXA10 expression acts as an unfavorable survival marker, although some lineages such as LIHC and MESO show a favorable association.

LUAD, LIHC, and DLBC are the cancer types where ANXA10 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.705	0.845	<.001	137	view →
LIHC	OS	Median	All	0.769	0.606	<.001	106	view →
DLBC	OS	Quartile	All	0.653	0.983	<.001	86	view →
HNSC	DFS	Quartile	II,III,IV	0.402	0.793	<.001	44	view →
THYM	DFS	Quartile	All	0.739	0.975	.003	44	view →
MESO	DFS	Tertile	II,III,IV	0.537	0.311	.008	42	view →
OV	OS	Quartile	All	0.469	0.313	.004	40	view →
COAD	OS	Median	III,IV	0.525	0.847	<.001	36	view →
BRCA	DFS	Quartile	All	0.933	0.873	.003	34	view →
ESCA	OS	Tertile	III,IV	0.293	0.585	.012	30	view →
SCLC	OS	Quartile	All	0.747	0.522	.039	22	view →
SKCM	OS	Median	All	0.833	0.740	.002	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

ANXA10–LUAD (DFS)

Open the LUAD breakdown →